Translation of virtual-pinhole magnifying PET technology to clinical whole-body cancer imaging

虚拟针孔放大PET技术在临床全身癌症成像中的转化

• 批准号: 10305587
• 负责人: YUAN-CHUAN TAI
• 金额: $ 53万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-12-04 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10305587
• 关键词: Address; Adopted; Beds; Cancer Detection; Cancer Patient; Clinic; Clinical; Clinical Research; Computed Tomography Scanners; Computer software; Costs and Benefits; Data; Data Set; Detection; Development; Devices; Diagnostic Neoplasm Staging; Diagnostic Sensitivity; Discipline of Nuclear Medicine; Disease; Disease Management; Disseminated Malignant Neoplasm; Distant Metastasis; Emission-Computed Tomography; Funding; Image; Image Enhancement; Imaging technology; Institution; Knowledge; Lesion; Letters; Location; Magnetic Resonance Imaging; Monitor; Motion; Multi-Institutional Clinical Trial; Neoplasm Metastasis; Noise; Nuclear Radiology; Outcome; Patients; Physicians; Positioning Attribute; Positron-Emission Tomography; Principal Investigator; Protocols documentation; Radiology Specialty; Research; Research Personnel; Resolution; Scanning; Signal Transduction; Staging; Surface; System; Technology; Thigh structure; Time; Translating; Translations; Uncertainty; Universities; Validation; Vision; Washington; X-Ray Computed Tomography; accurate diagnosis; attenuation; cancer diagnosis; cancer imaging; cancer type; cost effective; cranium; detection method; detection sensitivity; detector; diagnostic accuracy; human imaging; image reconstruction; imaging capabilities; imaging detection; imaging study; improved; in vivo imaging; innovation; interest; medical schools; molecular imaging; novel; novel imaging technology; programs; prototype; standard of care; statistics; success; technology development; treatment response; virtual; whole body imaging

Project Summary / Abstract FDG whole-body PET/CT imaging is a proven technique for the detection of primary and metastatic cancers. It is highly accurate and valuate for cancer staging, re-staging, and monitoring response to therapy for many types of cancers. Despite its success and broad clinical utility, there remains an unmet clinical challenge for the detection of small metastatic cancers that are much smaller than 1 cm. FDG PET/CT has been shown to have limited sensitivity for the detection of such small lesions, in some cases less than 50% of the time. We have developed a novel imaging technology called virtual-pinhole magnifying PET technology that can improve the image resolution of clinical PET/CT scanner to enhance its image resolution and to provide zoom- in images without compromising its body imaging capability. While this is a unique capability, it has not been adopted for clinical whole-body cancer imaging because the location of distant metastasis is often unknown. Therefore, one would not have prior knowledge on where to zoom-in during a whole-body imaging protocol. If on the other hand, one needs to scan the entire body first and then chooses a region of high uncertainty to zoom- in; this technology will require a two-step protocol which will significantly slow down clinical workflow. In this project, we formed a bi-directional partnership between the Washington University School of Medicine (WUSM) and Siemens Molecular Imaging (Siemens MI, Knoxville, TN) to overcome this specific limitation and translate an otherwise novel imaging technology to be suitable for clinical utility. We will jointly develop and validate the Augmented Whole-body Scanning via Magnifying PET (AWSM-PET) technology that will enhance the native image resolution of a PET scanner and is fully compatible with clinical whole-body cancer imaging applications. The added device will not slowdown clinical workflow because the magnifying PET data will be acquired simultaneously with the standard PET data when a patient undergoes a whole-body PET/CT scan. In addition to the standard (native) PET/CT images, AWSM-PET will provide a second set of PET images with higher resolution and counting statistics without additional scan time. This information-rich second data set is expected to further improve the diagnostic accuracy of whole-body PET/CT imaging for the detection of metastatic cancer. Upon completion of this project, we will have developed and validated a new capability that can improve the image resolution and counting statistics of a clinical whole-body PET/CT scanner. If the results of the initial human imaging trial show improvement in diagnostic sensitivity for metastatic cancer detection using a whole- body PET/CT equipped with the AWSM-PET technology, we will seek additional funding to conduct a multi- center clinical trial to fully quantify the improvement in diagnostic accuracy by AWSM-PET technology for the detection of metastatic cancers. The success of this novel in vivo imaging technology will address an unmet challenge of the standard-of-care whole-body PET/CT in detecting small metastatic cancers. The WUSM and Siemens MI partnership will accelerate the delivery of the AWSM-PET technology to end users in nuclear medicine and radiology clinics worldwide. Thus the proposed technology development will have highly significant and broad impact on patients who rely on whole-body PET/CT imaging for accurate diagnosis and optimal management of their diseases.

项目概要/摘要 FDG 全身 PET/CT 成像是一种经过验证的检测原发性和转移性癌症的技术。它 对于癌症分期、重新分期和监测多种类型的治疗反应非常准确且有价值 癌症。尽管它取得了成功并具有广泛的临床实用性，但仍然存在未满足的临床挑战 检测远小于 1 厘米的小型转移性癌症。 FDG PET/CT 已被证明具有 检测此类小病变的灵敏度有限，在某些情况下小于 50%。 我们开发了一种新型成像技术，称为虚拟针孔放大 PET 技术，可以 提高临床PET/CT扫描仪的图像分辨率，增强其图像分辨率并提供变焦- 在不影响其身体成像能力的情况下。虽然这是一项独特的功能，但尚未被广泛应用。 由于远处转移的位置通常未知，因此被用于临床全身癌症成像。 因此，人们不会先了解在全身成像协议期间放大哪里。如果 另一方面，需要先扫描整个身体，然后选择不确定性较高的区域进行缩放—— 在;这项技术需要一个两步协议，这将显着减慢临床工作流程。 在这个项目中，我们与华盛顿大学医学院建立了双向合作伙伴关系 （WUSM）和西门子分子成像（Siemens MI，诺克斯维尔，田纳西州）克服了这一特定限制并 将一种新颖的成像技术转化为适合临床应用的技术。我们将共同开发和 验证通过放大 PET (AWSM-PET) 技术增强的全身扫描，该技术将增强 PET 扫描仪的原始图像分辨率，与临床全身癌症成像完全兼容 应用程序。添加的设备不会减慢临床工作流程，因为放大的 PET 数据将 当患者接受全身 PET/CT 扫描时，与标准 PET 数据同时获取。在 除了标准（原始）PET/CT 图像外，AWSM-PET 将提供第二组 PET 图像 更高的分辨率和计数统计数据，无需额外的扫描时间。这个信息丰富的第二个数据集是 有望进一步提高全身PET/CT成像的诊断准确性 转移性癌症。 该项目完成后，我们将开发并验证一项新功能，可以改善 临床全身 PET/CT 扫描仪的图像分辨率和计数统计。如果最初的结果 人体成像试验表明，使用整体检测可提高转移性​​癌症检测的诊断灵敏度。 配备AWSM-PET技术的全身PET/CT，我们将寻求额外的资金来进行多 中心临床试验，以充分量化 AWSM-PET 技术对诊断准确性的改善 检测转移性癌症。这种新颖的体内成像技术的成功将解决一个未满足的问题 标准护理全身 PET/CT 在检测小型转移性癌症方面面临的挑战。世界大学联盟 与西门子 MI 的合作将加速向核能最终用户交付 AWSM-PET 技术 世界各地的医学和放射诊所。因此，所提出的技术开发将具有非常重要的意义 对依赖全身 PET/CT 成像进行准确诊断和最佳治疗的患者产生广泛影响 管理他们的疾病。